Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And Extends $208.9M Cash Runway Into First Half Of 2028
Benzinga Newsdesk 9 months ago
News
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026Phase 1 dose-escalation
- Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026
- Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
- Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026
- Selective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability over dual CBP/EP300; tracking to IND-enabling studies in 2026
- Strong balance sheet with cash, cash equivalents, and marketable securities of $208.9 million*, including proceeds from the equity financing, which is anticipated to close on January 13, 2026, and allows for continued investment in the pipeline and extends cash into the first half of 2028